Abstract: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.
Type:
Application
Filed:
August 20, 2001
Publication date:
February 28, 2002
Applicant:
Chiron Corporation
Inventors:
Derek O'Hagan, Gary Van Nest, Gary S. Ott, Manmohan Singh
Abstract: The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted reform a colloidal suspension having a light transmission of greater than or equal to 88% as measured spectrophotometrically.
Type:
Application
Filed:
August 30, 2001
Publication date:
February 28, 2002
Applicant:
American Cyanamid Company
Inventors:
Vincent James LaPosta, John Hayward Eldridge
Abstract: A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least one pharmaceutically acceptable and water-soluble salt of an organic anion and a metal cation.
Type:
Grant
Filed:
March 19, 1997
Date of Patent:
January 29, 2002
Assignee:
Societe d'Exploitation de Produits Pour les Industries
Chemiques (SEPPIC)
Abstract: Vaccine adjuvants comprising a sulpholipid polysaccharide in combination with an interface-forming constituent. The invention also provides a method for preparing a vaccine by emulsifying an aqueous solution of an antigen and a sulpholipid polysaccharide. The adjuvants are stable at high temperatures, and are at least as effective as conventional adjuvants. Their local toxicity, i.e. their reactogenicity, is generally lower than that of conventional adjuvants.
Abstract: A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least one pharmaceutically acceptable and water-soluble salt of an organic anion and a metal cation.
Abstract: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.
Type:
Grant
Filed:
May 2, 2000
Date of Patent:
October 23, 2001
Assignee:
Chiron Corporation
Inventors:
Derek O'Hagan, Gary Van Nest, Gary S. Ott, Manmohan Singh
Abstract: This invention relates to the topical treatment of keloids, hypertrophic scars and burn scars by the use of a selected protein kinase c inhibitor and an effective penetrating agent selected from lecithin organogel or poloxamer 407 lecithin organogel. The protein kinase c inhibitors may be selected from sphingosine, sphinganine, phytosphingosine, N-Acetylsphingosine, N-Hexanoylsphingosine, N-Octanoylsphingosine, curcumin, tetrahydrocurcumin, curcuminoids or apigenin.
Abstract: The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted reform a colloidal suspension having a light transmission of greater than or equal to 88% as measured spectrophotometrically.
Type:
Grant
Filed:
July 13, 1999
Date of Patent:
October 23, 2001
Assignee:
American Cyanamid Company
Inventors:
Vincent James LaPosta, John Hayward Eldridge
Abstract: An adjuvant composition, comprising a metabolizable oil and an emulsifying agent, wherein the oil and the detergent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter. In preferred embodiments, the emulsifying agent is also an immunostimulating agent, such as a lipophilic muramyl peptide. Alternatively, an immunostimulating agent separate from the emulsifying agent can be used.
Type:
Grant
Filed:
April 7, 1995
Date of Patent:
October 9, 2001
Assignee:
Chiron Corporation
Inventors:
Gary Van Nest, Gary Ott, Gail Barchfeld
Abstract: A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to prime T-helper cells of the immune system of the host and a subsequent administration to the host of a mixture of the T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.
Type:
Application
Filed:
April 7, 1998
Publication date:
September 6, 2001
Inventors:
CHARLES D. Y. SIA, PELE CHONG, MICHEL H. KLEIN
Abstract: The present invention provides a pharmaceutical composition containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof and a lecithin, and containing a saccharide if desired, which can be formulated into a liquid preparation, and which is suitable for the suppression of rejection in organ or bone marrow transplantation, for an immunosuppressive sustention therapy or for the treatment of autoimmune diseases.
Abstract: A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least one pharmaceutically acceptable and water-soluble salt of an organic anion and a metal cation.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
August 14, 2001
Assignee:
Societe d'Exploitation de Produits pour les Industries
Chimiques (S.E.P.P.I.C.)
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Grant
Filed:
May 24, 1995
Date of Patent:
August 7, 2001
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Syamal Raychaudhuri, William H. Rastetter
Abstract: A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least one pharmaceutically acceptable and water-soluble salt of an organic anion and a metal cation.
Type:
Grant
Filed:
June 6, 1997
Date of Patent:
June 26, 2001
Assignee:
Societe d'Exploitation de Produits pour les Industries
Chimque
Abstract: The present invention provides processes for the preparation of the KH-1 and N3 antigens, as well as related analgoues thereof, which are useful as anticancer therapeutics. The present invention also provides various intermediates useful in the preparation of KH-1 and N3 and analogues thereof. Additionally, the invention provides various compositions comprising any of the analogues of KH-1 and N3 available through the methods of the invention and pharmaceutical carriers useful in the treatment of subjects suffering from various forms of epithelial cancer.
Type:
Grant
Filed:
January 13, 1998
Date of Patent:
May 29, 2001
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Samuel J. Danishefsky, Prashant P. Deshpande, In Jong Kim, Philip Livingston, Hyun Jin Kim, Ragupathi Govindaswami, Tae Kyo Park
Abstract: Injectable water-in-oil emulsion possessing immunity adjuvant activity and which can be used in man and animals as vaccine or an immunological medicament comprising an oily phase comprising an oil , an aqueous phase and at least one emulsifier, wherein the oil of said oily phase is a substantially metabolizable oil or a mixture of substantially metabolizable oils and said emulsifiers or emulsifiers providing with said metabolizable oil a stable emulsion having immunity adjuvant activity and a viscosity of less than 400 mPa.s at 25° C.
Type:
Grant
Filed:
August 12, 1997
Date of Patent:
May 22, 2001
Assignee:
Rhone Merieux
Inventors:
Michel Emile Albert Riviere, Claude Roulet
Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.
Abstract: Disclosed are compositions and methods for enhancing the antibody and T cell response to cellular antigens by incorporating an immunopotentiating agent into the cellular membrane or into an intracellular compartment. Such adjuvant-incorporated cell compositions are useful in methods to increase immune responses against antigens, including immunologically cryptic tumor cell antigens, and may be employed to generate useful diagnostic antibodies, to elicit anti-tumor effects in immunized animals, and to significantly prolong survival in animals with cancer.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
April 17, 2001
Assignee:
John Wayne Cancer Institute
Inventors:
Mepur H. Ravindranath, Donald L. Morton
Abstract: An improved immunomodulatory therapy for enhancement of depressed host defense mechanisms and improving allograft survival rates comprising the use of omega-9 unsaturated fatty acids to alter the immune response associated with organ transplantation. It is administered optionally in conjunction with an immunomodulatory diet comprising arginine and its salts, or metabolic precursors of arginine, together with an immuno-suppressive treatment comprising the administration of cyclosporine or other immuno-suppressants and optionally, with or without a donor specific transfusion. An especially preferred source of the omega-9 unsaturated fatty acids is canola oil.
Type:
Grant
Filed:
June 30, 1998
Date of Patent:
April 3, 2001
Assignees:
Novartis Nutrition AG, University of Cincinnati
Inventors:
John F. Valente, J. Wesley Alexander, Cora K. Ogle, Norman A. Greenberg
Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic &bgr;-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.
Type:
Grant
Filed:
July 21, 1998
Date of Patent:
March 27, 2001
Assignee:
The Regents of the University of California
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Grant
Filed:
February 17, 1998
Date of Patent:
March 6, 2001
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Syamal Raychaudhuri, William H. Rastetter, Amelia Black